Member reports the following financial or other potential conflicts of interest: [Last Modified: 26 September 2008]
occassional adv bd/consulting fees from commercial entities which develop drugs for schizophrenia. Hold a European Regional Office patent concerned with gene expression patterns [potential {unlikely} assets donated to MPRC].